Literature DB >> 8093606

Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors.

S W Christianson1, L D Shultz, E H Leiter.   

Abstract

Precise definition of the role of both CD4 and CD8 T-cell subsets from NOD mice in the adoptive transfer of diabetes has been complicated by the possibility that endogenous T-cells may be recruited. Two newly created NOD congenic stocks, NOD.NON-Thy-1a and NOD/LtSz-scid, have been used as T-cell donors and recipients, respectively, to eliminate contributions from endogenous T-cells and thus to define the requirement for transferred T-cell subsets as a function of underlying diabetes development in the NOD donor. Total T-cells and T-cell subsets prepared from either prediabetic or diabetic NOD.NON-Thy-1a donors were adoptively transferred into 6-wk-old NOD-scid/scid recipients that were monitored for diabetes development. Both flow cytometric and histological analysis of recipient spleen and pancreas after adoptive transfer showed lymphocytes of donor (Thy1.1+) origin exclusively. Total T-cell and enriched CD4+ T-cell preparations from both diabetic and young prediabetic donors transferred diabetes to NOD-scid/scid recipients. However, the mean time to diabetes onset was doubled when CD4+ lymphocytes were isolated from prediabetic versus diabetic donors, and these transfers were complicated by the generation of small but significant numbers of CD8+ cells over time. Enriched CD8+ populations alone were unable to transfer disease. More rigorous exclusion of CD8+ cells by means of anti-CD8 MoAb treatment in vivo of the recipients of enriched CD4+ cells demonstrated a significant difference in the diabetogenic potency of CD4+ lymphocytes from diabetic versus nondiabetic donors. Diabetes was adoptively transferred to 58% of the recipients of enriched CD4+ lymphocytes from diabetic donors. In contrast, none of the recipients of enriched CD4+ lymphocytes from young prediabetic donors developed diabetes after MoAb treatment in vivo. The ability of a T-cell population to produce severe insulitis and sialitis in NOD-scid/scid recipients of T-cells closely paralleled its ability to induce diabetes. In an effort to suppress insulitis by suppression of macrophage migration to the islets, NOD-scid/scid mice were treated with silica in conjunction with adoptive transfer of T-cells from diabetic donors. Chronic silica treatment failed to deplete tissue macrophages and did not prevent diabetes development after transfer of unfractionated T-cells. Evidence is discussed indicating that the age-associated differences in ability of CD4+ T-cells to adoptively transfer diabetes in the absence of the CD8+ T-cells subset is a function of prior, chronic exposure of the CD4+ lymphocytes to beta-cell antigens in the donor.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093606     DOI: 10.2337/diab.42.1.44

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  140 in total

Review 1.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.

Authors:  Andrew D Vonberg; Maria Acevedo-Calado; Aaron R Cox; Susan L Pietropaolo; Roberto Gianani; Steven K Lundy; Massimo Pietropaolo
Journal:  JCI Insight       Date:  2018-12-06

3.  A minor subset of Batf3-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes.

Authors:  Stephen T Ferris; Javier A Carrero; James F Mohan; Boris Calderon; Kenneth M Murphy; Emil R Unanue
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

4.  T-cell response to proinsulin and insulin in type 1 and pretype 1 diabetes.

Authors:  D Dubois-LaForgue; J C Carel; P F Bougnères; J G Guillet; C Boitard
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

Review 5.  The non obese diabetic (NOD) mouse: a unique model for understanding the interaction between genetics and T cell responses.

Authors:  William M Ridgway
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 6.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 7.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

Review 8.  Use of nonobese diabetic mice to understand human type 1 diabetes.

Authors:  Terri C Thayer; S Brian Wilson; Clayton E Mathews
Journal:  Endocrinol Metab Clin North Am       Date:  2010-07-08       Impact factor: 4.741

9.  A diabetes-associated T-cell autoantigen maps to a telomeric locus on mouse chromosome 6.

Authors:  A Dallas-Pedretti; M McDuffie; K Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  Suppression of autoimmune diabetes by soluble galectin-1.

Authors:  Marcelo J Perone; Suzanne Bertera; William J Shufesky; Sherrie J Divito; Angela Montecalvo; Alicia R Mathers; Adriana T Larregina; Mabel Pang; Nilufer Seth; Kai W Wucherpfennig; Massimo Trucco; Linda G Baum; Adrian E Morelli
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.